

SINGAPORE
BIOTECH INVEST

21-22 March 2017

Singapore Exchange (SGX)

HONG KONG
BIOTECH INVEST

23-24 March 2017

KPMG Hong Kong

AUSTRALIA-CHINA
BIOTECH INVEST

27-28 March 2017

Shanghai Marriott Hotel City Centre

Cynata Therapeutics company profile:

Cynata Therapeutics Limited (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic allogeneic mesenchymal stem cell (MSC) platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. MSCs have a wide range of potential therapeutic applications, including stroke, cardiovascular disease and respiratory disease. By utilising induced pluripotent stem cells (iPSCs) as the starting material for manufacture of the therapeutic MSC product the proprietary Cymerus™ technology addresses a critical shortcoming in existing methods of production of MSCs for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. The Cymerus™ platform provides a source of MSCs that is independent of donor limitations and provides an “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical product business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position. Cynata has a strategic partnership with FUJIFILM and has approval to commence a Phase I clinical trial in GvHD.

